RecruitingRecruiting
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
NCT03680677 · Abramson Cancer Center at Penn Medicine
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
About this study
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Eligibility criteria
Eligibility Criteria Arm A:
* Age 60 years or older.
* New diagnosis of Acute Leukemia or MDS, or suspected diagnosis.
* Able to consent to the study.
Eligibility Criteria Arm B:
* Age 60 years or older with a hematologic malignancy.
* Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy.
* Able to consent to the study.
Study design
Enrollment target: 20 participants
Age groups: adult, older_adult
Timeline
Starts: 2018-09-21
Estimated completion: 2026-11
Last updated: 2025-07-31
Interventions
Procedure: Bone Marrow or Peripheral Blood Graft (BMT)Other: Cancer-directed Therapy or Best Supportive CareDiagnostic Test: Frailty Assessment
Primary outcomes
- • Non-Relapse Mortality (NRM) in Frail, Pre-Frail, and Non-Frail patients (1-month)
Sponsor
Abramson Cancer Center at Penn Medicine · other
Contacts & investigators
ContactShannon McCurdy, MD · contact · penncancertrials@emergingmed.com · 855-216-0098
InvestigatorShannon McCurdy, MD · principal_investigator, Abramson Cancer Center
All locations (1)
Abramson Cancer Center of the University of PennsylvaniaRecruiting
Philadelphia, Pennsylvania, United States